STOCKHOLM and LUND, Sweden, Nov. 8, 2005 (PRIMEZONE) -- Active Biotech (Stockholm:ACTI) has commenced enrollment for a clinical Phase I combination study of its candidate drug, ANYARA, with the cancer (chemotherapy) drug, Taxotere(r). The study is designed to evaluate the two drugs in combination as a treatment for non-small cell lung cancer.
This dose-escalation study, expected to include between 20 and 30 patients, will examine the response to increasing doses of ANYARA in combination with a fixed dose of Taxotere(r). Taxotere(r) will be administered according to the established dosing schedule; ANYARA will be dosed at levels expected to have an anti-tumor effect.
Professor Roger Cohen of Fox Chase Cancer Center in Philadelphia, PA (USA) is the principal investigator for the trial. The study will be conducted at clinics in the USA, Denmark and Russia.
Additionally, Active Biotech is conducting a clinical Phase I dose-escalation study of ANYARA-only that is currently ongoing in the USA, Norway and the U.K.
Lund 8 November, 2005
Active Biotech AB (publ) Sven Andreasson President & CEO
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex(r) for RA.
Active Biotech AB Box 724, SE-220 07 Lund Tel: +46 46-19 20 00 Fax: +46 46-19 20 50 www.activebiotech.com